Summary

The global radiotherapy market is expected to grow from USD 7.98 billion in 2026 to USD 10.68 billion by 2031, registering a CAGR of 6.0% during the forecast period. The advancements in radiotherapy technology are expected to significantly boost market growth in the coming years. However, the high costs of radiotherapy products may hinder market expansion. “The external beam radiotherapy segment held the largest share of the market in 2025.” By technology, the radiotherapy market is categorized into external beam radiotherapy and internal beam radiotherapy/brachytherapy. During the forecast period, the external beam radiotherapy segment is expected to hold the largest market share. This is due to its ability to accurately target tumors while minimizing exposure to surrounding healthy tissue. The growth of this segment is driven by the increasing adoption of advanced procedures and a rising demand for precision medicine. “The external beam radiotherapy procedures segment is expected to hold the largest share of the market in 2025.” By procedure, the radiotherapy market can be categorized into external beam radiotherapy and internal beam radiotherapy/brachytherapy procedures. The external beam radiotherapy procedures segment is expected to dominate the market during the forecast period. This is due to their accuracy, which allows for precise targeting of tumors while minimizing radiation exposure to healthy tissues. Additionally, external beam radiotherapy is commonly used to treat cancer. Innovations in image-guided and intensity-modulated radiotherapy systems are further driving the growth of this segment. “The hospital segment is expected to hold the largest share of the market in 2025.” By end user, the radiotherapy market is categorized into hospitals and standalone radiotherapy centers. In the coming years, the hospitals segment is expected to capture the largest share of the global radiotherapy market. This growth can be attributed to several factors, including a high patient volume, the availability of advanced radiotherapy equipment, and the increasing demand for comprehensive cancer treatment facilities within hospitals. Additionally, the expansion of hospitals in developing countries, investments in healthcare infrastructure, and the availability of trained oncologists will further support the growth of this segment. “The market in the APAC region is expected to register the highest growth rate during the forecast period.” The radiotherapy market is divided into five key regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America plays a significant role in the global radiotherapy market due to its established healthcare infrastructure, advanced radiotherapy equipment, favorable reimbursement policies, and the presence of key market players. However, the Asia Pacific region is expected to experience the highest growth rate during the forecast period. This growth is driven by the rising incidence of cancer, increased investment in healthcare, enhanced funding for oncology treatments, and advancements in healthcare infrastructure in countries such as China, India, and Japan, all of which have led to greater adoption of radiotherapy. A breakdown of the primary participants referred to for this report is provided below: ・ By Company Type: Tier 1 (40%), Tier 2 (30%), and Tier 3 (30%) ・ By Designation: Directors (18%), C-level Executives (27%), and Other Designations (55%) ・ By Region: North America (50%), Europe (20%), Asia Pacific (10%), Latin America (10%), and the Middle East & Africa (10%) The prominent players in the radiotherapy market are Siemens Healthineers GmbH (Germany), Elekta (Sweden), Accuray Incorporated (US), IBA WORLDWIDE (Belgium), ViewRay Technologies, Inc (US), Perspective Therapeutics, Inc. (US), Hitachi High Tech Corporation (Japan), Sumitomo Heavy Industries Ltd. (Japan), Carl Zeiss Meditec AG (Germany), and Koninklijke Philips N.V. (Netherlands), among others. Research Coverage This report studies the radiotherapy market based on offering, technology, application, procedure, end user, and region. It also covers the factors affecting market growth, analyzes the opportunities and challenges in the market, and provides details on the competitive landscape among market leaders. Furthermore, the report analyzes micromarkets by their individual growth trends and forecasts revenue for market segments across five main regions (and the countries within these regions). Reasons to Buy the Report The report will enable established firms, as well as entrants/smaller firms, to gauge the pulse of the market, which, in turn, will help them garner a larger market share. Firms purchasing the report could use one or a combination of the following strategies to strengthen their market presence. This report provides insights into the following pointers: ・ Analysis of key drivers (advancements in radiotherapy treatment technology, growing patient population, increasing initiatives to promote radiotherapy awareness, and growing use of particle therapy for cancer treatment), restraints (high cost of advanced lab consumables and environmental sustainability concerns), opportunities (lack of adequate healthcare infrastructure, high capital cost of radiotherapy, and complexity of radiotherapy), and challenges (dearth of skilled personnel, difficulties in visualizing tumors during radiotherapy, and risk of Radiation Exposure) influencing the growth of the radiotherapy market. ・ Market Penetration: Comprehensive information on the product portfolios offered by the top players in the radiotherapy market. ・ Product Development/Innovation: Detailed insights on the upcoming trends, R&D activities, and product developments in the radiotherapy market. ・ Market Development: Comprehensive information on lucrative emerging regions. ・ Market Diversification: Exhaustive information about new products, growing geographies, and recent developments in the radiotherapy market. ・ Competitive Assessment: In-depth assessment of market segments, growth strategies, revenue analysis, and products of the leading market players.

ページTOPに戻る

Table of Contents

1 INTRODUCTION 29
1.1 STUDY OBJECTIVES 29
1.2 MARKET DEFINITION 29
1.3 MARKET SCOPE 30
1.3.1 MARKET SEGMENTATION AND REGIONAL SCOPE 30
1.3.2 INCLUSIONS & EXCLUSIONS 31
1.3.3 YEARS CONSIDERED 32
1.3.4 CURRENCY CONSIDERED 32
1.4 STAKEHOLDERS 32
1.5 SUMMARY OF CHANGES 33
2 EXECUTIVE SUMMARY 34
2.1 MARKET HIGHLIGHTS AND KEY INSIGHTS 34
2.2 KEY MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS 35
2.3 DISRUPTIVE TRENDS IN RADIOTHERAPY MARKET 36
2.4 HIGH-GROWTH SEGMENTS 37
2.5 REGIONAL SNAPSHOT: MARKET SIZE, GROWTH RATE, AND FORECAST 38
3 PREMIUM INSIGHTS 39
3.1 RADIOTHERAPY MARKET OVERVIEW 39
3.2 RADIOTHERAPY MARKET, BY REGION 40
3.3 NORTH AMERICA: RADIOTHERAPY MARKET, BY TECHNOLOGY AND COUNTRY 40
3.4 GEOGRAPHIC SNAPSHOT OF RADIOTHERAPY MARKET 41
4 MARKET OVERVIEW 42
4.1 INTRODUCTION 42
4.2 MARKET DYNAMICS 42
4.2.1 DRIVERS 43
4.2.1.1 Advancements in radiotherapy treatment 43
4.2.1.2 AI and automation in treatment planning 45
4.2.1.3 Increasing government investments and awareness initiatives for cancer care 46
4.2.2 RESTRAINTS 46
4.2.2.1 High costs associated with radiotherapy systems such as proton therapy and advanced linear accelerators 46
4.2.2.2 Limited access to advanced radiotherapy infrastructure and skilled workforce in low- and middle-income countries 47
4.2.2.3 Shortage of skilled radiation oncologists, medical physicists, and trained technicians 47
 
4.2.3 OPPORTUNITIES 47
4.2.3.1 Emerging markets offer significant growth potential for radiotherapy technologies 47
4.2.3.2 Integration of radiotherapy with immunotherapy and systemic therapies 48
4.2.3.3 Growing adoption of outpatient radiotherapy and hypofractionated treatment regimens 49
4.2.4 CHALLENGES 50
4.2.4.1 Increasing cybersecurity and data protection challenges in digital radiotherapy ecosystems 50
4.2.4.2 Patient safety concerns and radiation exposure risks 50
4.3 UNMET NEEDS 51
4.4 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS 52
5 INDUSTRY TRENDS 54
5.1 PORTER’S FIVE FORCES ANALYSIS 54
5.1.1 INTENSITY OF COMPETITIVE RIVALRY 55
5.1.2 BARGAINING POWER OF SUPPLIERS 55
5.1.3 BARGAINING POWER OF BUYERS 56
5.1.4 THREAT OF SUBSTITUTES 56
5.1.5 THREAT OF NEW ENTRANTS 56
5.2 MACROECONOMIC OUTLOOK 56
5.2.1 GDP TRENDS AND FORECAST 56
5.2.2 TRENDS IN GLOBAL RADIOTHERAPY INDUSTRY 57
5.3 VALUE CHAIN ANALYSIS 57
5.3.1 RESEARCH & DEVELOPMENT 58
5.3.2 PROCUREMENT & MANUFACTURING 58
5.3.3 MARKETING, SALES, AND DISTRIBUTION 58
5.4 ECOSYSTEM ANALYSIS 59
5.5 PRICING ANALYSIS 59
5.5.1 AVERAGE SELLING PRICE TREND, BY REGION 60
5.6 TRADE ANALYSIS 62
5.6.1 IMPORT DATA (HS CODE 902214) 62
5.6.2 EXPORT DATA (HS CODE 902214) 63
5.7 KEY CONFERENCES & EVENTS, 2026–2027 64
5.8 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 64
5.9 INVESTMENT & FUNDING SCENARIO 65
5.10 CASE STUDY ANALYSIS 67
5.10.1 SBRT’S ROLE IN MINIMIZING RADIATION RISK IN ELDERLY PATIENTS 67
5.10.2 RADIOTHERAPY FOR BREAST CANCER IN PATIENTS WITH HEREDITARY COPROPORPHYRIA 67
5.10.3 RADIATION THERAPY TREATMENT FOR TRANSITIONAL CELL CARCINOMA OF DISTAL URETHRA 68
 
5.11 IMPACT OF 2025 US TARIFF - RADIOTHERAPY MARKET 68
5.11.1 KEY TARIFF RATES 69
5.11.2 PRICE IMPACT ANALYSIS 69
5.11.3 IMPACT ON COUNTRIES/REGIONS 70
5.11.4 IMPACT ON END-USE INDUSTRIES 71
6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS 72
6.1 KEY TECHNOLOGIES 72
6.1.1 MR-GUIDED ADAPTIVE RADIOTHERAPY 72
6.1.2 ARTIFICIAL INTELLIGENCE-DRIVEN TREATMENT PLANNING 72
6.1.3 PROTON AND PARTICLE THERAPY 73
6.2 COMPLEMENTARY TECHNOLOGIES 73
6.2.1 ADVANCED TREATMENT PLANNING SYSTEMS AND AI-ENABLED
DECISION SUPPORT 73
6.2.2 CLOUD-BASED AND REMOTE RADIOTHERAPY PLATFORMS 74
6.3 PATENT ANALYSIS 74
6.3.1 INNOVATIONS AND PATENT REGISTRATIONS 76
6.4 FUTURE APPLICATIONS 77
6.5 IMPACT OF AI/GEN AI ON RADIOTHERAPY MARKET 77
6.5.1 TOP USE CASES AND MARKET POTENTIAL 79
6.5.2 BEST PRACTICES FOLLOWED BY MANUFACTURERS IN
RADIOTHERAPY MARKET 80
6.5.3 CASE STUDIES RELATED TO AI IMPLEMENTATION IN RADIOTHERAPY MARKET 80
6.5.4 INTERCONNECTED ECOSYSTEM AND IMPACT ON MARKET PLAYERS 81
6.5.5 CLIENT'S READINESS TO ADOPT GENERATIVE AI IN RADIOTHERAPY MARKET 82
6.6 SUCCESS STORIES AND REAL-WORLD APPLICATIONS 82
7 REGULATORY LANDSCAPE 84
7.1 REGIONAL REGULATIONS AND COMPLIANCE 84
7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 84
7.1.2 INDUSTRY STANDARDS 86
7.1.2.1 North America 86
7.1.2.1.1 US 86
7.1.2.1.2 Canada 87
7.1.2.2 Europe 88
7.1.2.3 Asia Pacific 88
7.1.2.3.1 China 88
7.1.2.3.2 Japan 89
7.1.2.3.3 India 90
 
8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 91
8.1 DECISION-MAKING PROCESS 91
8.2 KEY STAKEHOLDERS INVOLVED IN BUYING PROCESS AND THEIR EVALUATION CRITERIA 92
8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS 92
8.2.2 BUYING CRITERIA 92
8.3 ADOPTION BARRIERS AND INTERNAL CHALLENGES 93
8.4 UNMET NEEDS FROM END-USERS 94
9 RADIOTHERAPY MARKET, BY SYSTEM AND SOFTWARE & SERVICE 95
9.1 INTRODUCTION 96
9.2 SYSTEMS 96
9.2.1 INCREASING ADOPTION OF AI-ENABLED AND IMAGE-GUIDED RADIOTHERAPY SYSTEMS TO DRIVE GROWTH 96
9.3 SOFTWARE & SERVICES 97
9.3.1 INCREASING ADOPTION OF INTEGRATED ONCOLOGY SOFTWARE PLATFORMS TO SUPPORT MARKET GROWTH 97
10 RADIOTHERAPY MARKET, BY APPLICATION 99
10.1 INTRODUCTION 100
10.2 EXTERNAL BEAM RADIOTHERAPY 100
10.2.1 PROSTATE CANCER 101
10.2.1.1 High incidence rate and efficiency of EBRT in prostate cancer treatment to support growth 101
10.2.2 BREAST CANCER 102
10.2.2.1 Therapeutic benefits of EBRT to drive market 102
10.2.3 LUNG CANCER 103
10.2.3.1 High prevalence of lung cancer and efficiency of EBRT to drive market 103
10.2.4 HEAD & NECK CANCER 104
10.2.4.1 Increasing preference for noninvasive treatment of head & neck cancers to drive market 104
10.2.5 COLORECTAL CANCER 105
10.2.5.1 High incidence of colorectal cancer to support market growth 105
10.2.6 OTHER EBRT APPLICATIONS 106
10.3 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY 107
10.3.1 PROSTATE CANCER 108
10.3.1.1 Precision of brachytherapy to drive market 108
10.3.2 GYNECOLOGICAL CANCER 109
10.3.2.1 Availability of alternatives to hinder adoption of brachytherapy 109
10.3.3 BREAST CANCER 110
10.3.3.1 Growing adoption of accelerated partial breast irradiation drives breast brachytherapy utilization 110
10.3.4 CERVICAL CANCER 111
10.3.4.1 MRI-guided adaptive brachytherapy and AI-enabled planning drive advances in cervical cancer treatment 111
10.3.5 PENILE CANCER 112
10.3.5.1 Increasing awareness of organ-preservation strategies to drive market 112
10.3.6 OTHER IBRT APPLICATIONS 113
11 RADIOTHERAPY MARKET, BY PROCEDURE 114
11.1 INTRODUCTION 115
11.2 EXTERNAL BEAM RADIOTHERAPY 115
11.2.1 IMAGE-GUIDED RADIOTHERAPY 117
11.2.1.1 Growing adoption of real-time imaging and adaptive workflows to support market growth 117
11.2.2 INTENSITY-MODULATED RADIOTHERAPY 118
11.2.2.1 Growing adoption of hypofractionation and adaptive treatment planning to propel market 118
11.2.3 PARTICLE THERAPY 119
11.2.3.1 Advancements in treatment planning systems and expansion of proton therapy facilities to drive adoption 119
11.2.4 3D CONFORMAL RADIOTHERAPY 120
11.2.4.1 Continued utilization in resource-constrained settings to support adoption of 3D-CRT 120
11.2.5 STEREOTACTIC RADIOTHERAPY 121
11.2.5.1 Expanding clinical applications and hypofractionated treatment approaches to propel adoption 121
11.2.6 OTHER EBRT PROCEDURES 122
11.3 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY 123
11.3.1 LDR BRACHYTHERAPY 124
11.3.1.1 Low risk of radiation exposure to surrounding tissues to drive adoption 124
11.3.2 HDR BRACHYTHERAPY 125
11.3.2.1 Advancements in image-guided planning and dose optimization to drive growth 125
11.3.3 PDR BRACHYTHERAPY 126
11.3.3.1 Better radiation safety, easier prospective planning, and precise dose shaping to drive adoption 126
12 RADIOTHERAPY MARKET, BY TECHNOLOGY 127
12.1 INTRODUCTION 128
12.2 EXTERNAL BEAM RADIOTHERAPY 128
12.2.1 LINACS 129
12.2.1.1 Conventional LINACs 131
12.2.1.1.1 Long treatment duration to limit adoption 131
12.2.1.2 Stereotactic advanced electron/cobalt-60 LINACs 131
12.2.1.2.1 CyberKnife 132
12.2.1.2.1.1 Precise radiation delivery with robotic correction capabilities to drive market 132
12.2.1.2.2 Gamma Knife 134
12.2.1.2.2.1 Advancements in precision intracranial radiosurgery to drive adoption 134
12.2.1.2.3 TomoTherapy 135
12.2.1.2.3.1 Accurate targeting of tumors and minimization of exposure to surrounding healthy tissues to drive adoption 135
12.2.1.3 MRI LINACs 136
12.2.1.3.1 Real-time imaging advantage to propel growth 136
12.2.2 PARTICLE THERAPY 137
12.2.2.1 Cyclotrons 138
12.2.2.1.1 Enhanced outcomes and other advantages to boost adoption 138
12.2.2.2 Synchrotrons 139
12.2.2.2.1 Increasing investments in synchrotron facilities to drive market 139
12.2.2.3 Synchrocyclotrons 140
12.2.2.3.1 Compact synchrocyclotron innovations support adoption despite infrastructure challenges 140
12.2.3 CONVENTIONAL COBALT-60 TELETHERAPY 141
12.2.3.1 Complex dose delivery planning and radiation exposure to limit market adoption 141
12.3 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY 142
12.3.1 SEEDS 143
12.3.1.1 Adverse effects associated with brachytherapy seeds to limit adoption 143
12.3.2 AFTERLOADERS 144
12.3.2.1 Proper positioning and better control of isotopes in modern afterloaders to drive demand 144
12.3.3 IORT SYSTEMS 145
12.3.3.1 Growing clinical evidence supporting long-term efficacy to drive adoption 145
12.3.4 APPLICATORS 146
12.3.4.1 High risk of radiation exposure in manual applicators to limit growth 146
13 RADIOTHERAPY MARKET, BY END USER 148
13.1 INTRODUCTION 149
13.2 HOSPITALS 149
13.2.1 INCREASING ADOPTION OF AI-ENABLED AND PRECISION RADIATION THERAPY SOLUTIONS TO DRIVE MARKET 149
13.3 INDEPENDENT RADIOTHERAPY CENTERS 150
13.3.1 EXPANSION OF RADIOTHERAPY INFRASTRUCTURE AND COMMUNITY-BASED CANCER CARE TO PROPEL MARKET 150
 
14 RADIOTHERAPY MARKET, BY REGION 152
14.1 INTRODUCTION 153
14.2 NORTH AMERICA 153
14.2.1 US 159
14.2.1.1 Favorable reimbursement scenario to drive growth 159
14.2.2 CANADA 161
14.2.2.1 Favorable initiatives from government and private organizations to boost market 161
14.3 EUROPE 164
14.3.1 GERMANY 169
14.3.1.1 Availability of novel radiotherapy products to drive market 169
14.3.2 FRANCE 171
14.3.2.1 Presence of advanced healthcare systems to augment growth 171
14.3.3 UK 173
14.3.3.1 Growing adoption of advanced radiotherapy technologies and rising cancer burden to drive market 173
14.3.4 SPAIN 176
14.3.4.1 Adoption of advanced radiotherapy technologies to drive market 176
14.3.5 ITALY 178
14.3.5.1 Rising adoption of advanced radiotherapy technologies and strong research ecosystem to support market growth 178
14.3.6 REST OF EUROPE 180
14.4 ASIA PACIFIC 181
14.4.1 JAPAN 187
14.4.1.1 Favorable reimbursement policies to propel market 187
14.4.2 CHINA 189
14.4.2.1 Precision oncology investments to drive market 189
14.4.3 INDIA 192
14.4.3.1 Growing cancer burden, infrastructure investments, and advanced technology adoption to drive market 192
14.4.4 SOUTH KOREA 194
14.4.4.1 Rising investments in heavy-ion therapy infrastructure to propel market 194
14.4.5 AUSTRALIA 196
14.4.5.1 Growing cancer cases to fuel market 196
14.4.6 REST OF ASIA PACIFIC 198
14.5 LATIN AMERICA 199
14.5.1 BRAZIL 205
14.5.1.1 Increasing prevalence of cancer to fuel market 205
14.5.2 MEXICO 207
14.5.2.1 Expanding oncology infrastructure and precision radiotherapy adoption to drive growth 207
14.5.3 REST OF LATIN AMERICA 209
14.6 MIDDLE EAST & AFRICA 211
14.6.1 GCC COUNTRIES 216
14.6.1.1 Increasing investments in advanced oncology infrastructure
to propel market 216
14.6.2 REST OF MIDDLE EAST & AFRICA 218
15 COMPETITIVE LANDSCAPE 220
15.1 INTRODUCTION 220
15.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 220
15.2.1 KEY PLAYER COMPETITIVE STRATEGIES IN RADIOTHERAPY MARKET,
JANUARY 2022–MAY 2026 220
15.3 REVENUE ANALYSIS, 2021–2025 224
15.4 MARKET SHARE ANALYSIS, 2025 225
15.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025 227
15.5.1 STARS 227
15.5.2 EMERGING LEADERS 227
15.5.3 PERVASIVE PLAYERS 227
15.5.4 PARTICIPANTS 227
15.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025 229
15.5.5.1 Company footprint 229
15.5.5.2 Region footprint 230
15.5.5.3 Technology footprint 230
15.5.5.4 Application footprint 231
15.5.5.5 End-user footprint 232
15.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 232
15.6.1 PROGRESSIVE COMPANIES 232
15.6.2 RESPONSIVE COMPANIES 232
15.6.3 DYNAMIC COMPANIES 233
15.6.4 STARTING BLOCKS 233
15.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025 234
15.6.5.1 Detailed list of key startups/SMEs, 2025 234
15.6.5.2 Competitive benchmarking of key startups/SMEs, 2025 235
15.7 COMPANY VALUATION & FINANCIAL METRICS 236
15.8 BRAND COMPARISON 237
15.9 COMPETITIVE SCENARIO 238
15.9.1 PRODUCT LAUNCHES & APPROVALS 238
15.9.2 DEALS 240
15.9.3 EXPANSIONS 241
 
16 COMPANY PROFILES 242
16.1 KEY PLAYERS 242
16.1.1 SIEMENS HEALTHINEERS AG 242
16.1.1.1 Business overview 242
16.1.1.2 Products/Solutions/Services offered 244
16.1.1.3 Recent developments 245
16.1.1.3.1 Product approvals 245
16.1.1.3.2 Deals 246
16.1.1.4 MnM view 247
16.1.1.4.1 Key strengths 247
16.1.1.4.2 Strategic choices 248
16.1.1.4.3 Weaknesses & competitive threats 248
16.1.2 ELEKTA 249
16.1.2.1 Business overview 249
16.1.2.2 Products/Solutions/Services offered 250
16.1.2.3 Recent developments 251
16.1.2.3.1 Product launches & approvals 251
16.1.2.3.2 Deals 252
16.1.2.3.3 Expansions 254
16.1.2.4 MnM view 254
16.1.2.4.1 Key strengths 254
16.1.2.4.2 Strategic choices 254
16.1.2.4.3 Weaknesses & competitive threats 254
16.1.3 ACCURAY INCORPORATED 255
16.1.3.1 Business overview 255
16.1.3.2 Products/Solutions/Services offered 256
16.1.3.3 Recent developments 257
16.1.3.3.1 Product launches & approvals 257
16.1.3.3.2 Deals 258
16.1.3.3.3 Expansions 259
16.1.3.4 MnM view 259
16.1.3.4.1 Key strengths 259
16.1.3.4.2 Strategic choices 259
16.1.3.4.3 Weaknesses & competitive threats 259
16.1.4 IBA WORLDWIDE 260
16.1.4.1 Business overview 260
16.1.4.2 Products/Solutions/Services offered 261
16.1.4.3 Recent developments 262
16.1.4.3.1 Products launches 262
16.1.4.3.2 Deals 263
16.1.4.4 MnM view 264
16.1.4.4.1 Key strengths 264
16.1.4.4.2 Strategic choices 264
16.1.4.4.3 Weaknesses & competitive threats 265
16.1.5 VIEWRAY SYSTEMS, INC. 266
16.1.5.1 Business overview 266
16.1.5.2 Products/Solutions/Services offered 266
16.1.5.3 Recent developments 267
16.1.5.3.1 Product approvals 267
16.1.5.3.2 Deals 267
16.1.6 GT MEDICAL TECHNOLOGIES, INC. 269
16.1.6.1 Business overview 269
16.1.6.2 Products/Solutions/Services offered 269
16.1.7 HITACHI HIGH-TECH CORPORATION 270
16.1.7.1 Business overview 270
16.1.7.2 Products/Solutions/Services offered 272
16.1.7.3 Recent developments 272
16.1.7.3.1 Deals 272
16.1.8 SUMITOMO HEAVY INDUSTRIES, LTD. 273
16.1.8.1 Business overview 273
16.1.8.2 Products/Solutions/Services offered 274
16.1.9 ZEISS GROUP 275
16.1.9.1 Business overview 275
16.1.9.2 Products/solutions/services offered 277
16.1.9.3 Recent developments 277
16.1.9.3.1 Products launches 277
16.1.10 MIM SOFTWARE INC. 278
16.1.10.1 Business overview 278
16.1.10.2 Products/Solutions/Services offered 278
16.1.10.3 Recent developments 279
16.1.10.3.1 Product launches & approvals 279
16.1.10.3.2 Deals 279
16.1.11 PANACEA MEDICAL TECHNOLOGIES PVT. LTD. 280
16.1.11.1 Business overview 280
16.1.11.2 Products/Solutions/Services offered 280
16.1.11.3 Recent developments 281
16.1.11.3.1 Product launches 281
16.1.11.3.2 Deals 281
16.1.12 PROVISION HEALTHCARE 282
16.1.12.1 Business overview 282
16.1.12.2 Products/Solutions/Services offered 282
16.1.13 MEVION MEDICAL SYSTEMS 283
16.1.13.1 Business overview 283
16.1.13.2 Products/Solutions/Services offered 283
16.1.13.3 Recent developments 284
16.1.13.3.1 Product launches & approvals 284
16.1.13.3.2 Deals 284
16.1.14 KONINKLIJKE PHILIPS N.V. 286
16.1.14.1 Business overview 286
16.1.14.2 Products/Solutions/Services offered 287
16.1.14.3 Recent developments 288
16.1.14.3.1 Product launches 288
16.2 OTHER PLAYERS 289
16.2.1 SHINVA MEDICAL INSTRUMENT CO., LTD. 289
16.2.2 BRAINLAB AG 290
16.2.3 RAYSEARCH LABORATORIES 291
16.2.4 INTRAOP MEDICAL, INC. 292
16.2.5 OPTIVUS PROTON THERAPY, INC. 293
16.2.6 BEBIG MEDICAL 294
16.2.7 P-CURE 295
16.2.8 THERAGENICS CORPORATION 296
16.2.9 PROTOM INTERNATIONAL 297
16.2.10 DOSISOFT SA 298
16.2.11 ISOAID, LLC 299
16.2.12 MAGNETTX ONCOLOGY SOLUTIONS LTD. 300
17 RESEARCH METHODOLOGY 301
17.1 RESEARCH DATA 301
17.1.1 SECONDARY DATA 302
17.1.1.1 Objectives of secondary research 302
17.1.1.2 List of secondary sources 303
17.1.2 PRIMARY DATA 303
17.1.2.1 Key data from primary sources 304
17.1.2.2 Key industry insights 305
17.2 MARKET ESTIMATION METHODOLOGY 306
17.2.1 BOTTOM-UP APPROACH 307
17.2.2 REVENUE MAPPING-BASED MARKET ESTIMATION 307
17.2.3 USAGE-BASED MARKET ESTIMATION 309
17.2.4 PRIMARY RESEARCH VALIDATION 310
17.2.5 TOP-DOWN APPROACH 311
17.3 DATA TRIANGULATION AND MARKET BREAKDOWN 312
17.4 MARKET SHARE ASSESSMENT 313
17.5 RESEARCH ASSUMPTIONS 314
17.6 RESEARCH LIMITATIONS 314
17.7 RISK ASSESSMENT 315
17.7.1 RISK ASSESSMENT ANALYSIS 315
18 APPENDIX 316
18.1 DISCUSSION GUIDE 316
18.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 323
18.3 CUSTOMIZATION OPTIONS 325
18.4 RELATED REPORTS 325
18.5 AUTHOR DETAILS 326

ページTOPに戻る

List of Tables/Graphs

TABLE 1 RADIOTHERAPY MARKET: INCLUSION/EXCLUSION DETAILS 31
TABLE 2 DIFFERENT TYPES OF EXTERNAL BEAM RADIATION THERAPY (EBRT) TECHNIQUES AND ASSOCIATED ADVANTAGES AND DISADVANTAGES 43
TABLE 3 TREATMENT-RELATED EFFECTS AND TOXICITY CONCERNS 50
TABLE 4 RADIOTHERAPY MARKET: CURRENT UNMET NEEDS 51
TABLE 5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS 52
TABLE 6 RADIOTHERAPY MARKET: PORTER’S FIVE FORCES ANALYSIS 54
TABLE 7 AVERAGE SELLING PRICE TREND OF RADIOTHERAPY SYSTEMS,
BY REGION, 2023–2025 61
TABLE 8 IMPORT DATA FOR HS CODE 902214-COMPLIANT PRODUCTS, BY COUNTRY, 2021–2025 (USD) 62
TABLE 9 EXPORT DATA FOR HS CODE 902214-COMPLIANT PRODUCTS, BY COUNTRY, 2021–2025 (USD) 63
TABLE 10 RADIOTHERAPY MARKET: KEY CONFERENCES & EVENTS, 2026–2027 64
TABLE 11 US-ADJUSTED RECIPROCAL TARIFF RATES IN MEDTECH INDUSTRY 69
TABLE 12 TARIFF-INDUCED PRICE INCREASES FOR HEALTHCARE PRODUCTS 69
TABLE 13 RADIOTHERAPY MARKET: INNOVATIONS AND PATENT REGISTRATIONS,
2020–2026 76
TABLE 14 KEY CLINICAL TRIALS EVALUATING ARTIFICIAL INTELLIGENCE IN RADIOTHERAPY 78
TABLE 15 KEY AI USE CASES AND MARKET POTENTIAL IN RADIOTHERAPY MARKET 79
TABLE 16 KEY CLINICAL CASE STUDIES OF ARTIFICIAL INTELLIGENCE APPLICATIONS IN RADIOTHERAPY 81
TABLE 17 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 84
TABLE 18 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 85
TABLE 19 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 85
TABLE 20 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 85
TABLE 21 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 86
TABLE 22 US: MEDICAL DEVICE REGULATORY APPROVAL PROCESS 87
TABLE 23 CLASS II PRESCRIBED EQUIPMENT CERTIFICATES 87
TABLE 24 JAPAN: MEDICAL DEVICE CLASSIFICATION UNDER PMDA 89
TABLE 25 INDIA: MEDICAL DEVICE CLASSIFICATION UNDER CDSCO 90
TABLE 26 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF
RADIOTHERAPY SYSTEMS 92
TABLE 27 KEY BUYING CRITERIA FOR RADIOTHERAPY SYSTEMS 93
TABLE 28 RADIOTHERAPY MARKET: CURRENT UNMET NEEDS 94
TABLE 29 RADIOTHERAPY MARKET, BY SYSTEM AND SOFTWARE &
SERVICE 2024–2031 (USD MILLION) 96
TABLE 30 RADIOTHERAPY SYSTEMS MARKET, BY REGION, 2024–2031 (USD MILLION) 97
TABLE 31 RADIOTHERAPY SOFTWARE & SERVICES MARKET, BY REGION,
2024–2031 (USD MILLION) 98
TABLE 32 RADIOTHERAPY MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 100
TABLE 33 EXTERNAL BEAM RADIOTHERAPY APPLICATIONS MARKET, BY TYPE,
2024–2031 (USD MILLION) 100
TABLE 34 EXTERNAL BEAM RADIOTHERAPY APPLICATIONS MARKET, BY REGION,
2024–2031 (USD MILLION) 101
TABLE 35 EXTERNAL BEAM RADIOTHERAPY APPLICATIONS MARKET FOR PROSTATE
CANCER, BY REGION, 2024–2031 (USD MILLION) 102
TABLE 36 EXTERNAL BEAM RADIOTHERAPY APPLICATIONS MARKET FOR
BREAST CANCER, BY REGION, 2024–2031 (USD MILLION) 103
TABLE 37 EXTERNAL BEAM RADIOTHERAPY APPLICATIONS MARKET FOR LUNG
CANCER, BY REGION, 2024–2031 (USD MILLION) 104
TABLE 38 EXTERNAL BEAM RADIOTHERAPY APPLICATIONS MARKET FOR HEAD &
NECK CANCER, BY REGION, 2024–2031 (USD MILLION) 105
TABLE 39 EXTERNAL BEAM RADIOTHERAPY APPLICATIONS MARKET FOR COLORECTAL CANCER, BY REGION, 2024–2031 (USD MILLION) 106
TABLE 40 OTHER EBRT APPLICATIONS MARKET, BY REGION, 2024–2031 (USD MILLION) 107
TABLE 41 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY APPLICATIONS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 107
TABLE 42 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY APPLICATIONS MARKET,
BY REGION, 2024–2031 (USD MILLION) 108
TABLE 43 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY APPLICATIONS MARKET
FOR PROSTATE CANCER, BY REGION, 2024–2031 (USD MILLION) 109
TABLE 44 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY APPLICATIONS MARKET
FOR GYNECOLOGICAL CANCER, BY REGION, 2024–2031 (USD MILLION) 110
TABLE 45 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY APPLICATIONS MARKET
FOR BREAST CANCER, BY REGION, 2024–2031 (USD MILLION) 111
TABLE 46 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY APPLICATIONS MARKET
FOR CERVICAL CANCER, BY REGION, 2024–2031 (USD MILLION) 112
TABLE 47 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY APPLICATIONS MARKET
FOR PENILE CANCER, BY REGION, 2024–2031 (USD MILLION) 113
TABLE 48 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY APPLICATIONS MARKET
FOR OTHER IBRT APPLICATIONS, BY REGION, 2024–2031 (USD MILLION) 113
TABLE 49 RADIOTHERAPY MARKET, BY PROCEDURE, 2024–2031 (USD MILLION) 115
TABLE 50 EXTERNAL BEAM RADIOTHERAPY PROCEDURES MARKET, BY TYPE,
2024–2031 (USD MILLION) 116
TABLE 51 EXTERNAL BEAM RADIOTHERAPY PROCEDURES MARKET, BY REGION,
2024–2031 (USD MILLION) 116
TABLE 52 IMAGE-GUIDED RADIOTHERAPY MARKET, BY REGION, 2024–2031 (USD MILLION) 117
TABLE 53 INTENSITY-MODULATED RADIOTHERAPY MARKET, BY REGION,
2024–2031 (USD MILLION) 118
TABLE 54 PARTICLE THERAPY MARKET, BY REGION, 2024–2031 (USD MILLION) 120
TABLE 55 3D CONFORMAL RADIOTHERAPY MARKET, BY REGION,
2024–2031 (USD MILLION) 121
TABLE 56 STEREOTACTIC RADIOTHERAPY MARKET, BY REGION, 2024–2031 (USD MILLION) 122
TABLE 57 OTHER EBRT PROCEDURES MARKET, BY REGION, 2024–2031 (USD MILLION) 123
TABLE 58 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY PROCEDURES MARKET,
BY TYPE, 2024–2031 (USD MILLION) 123
TABLE 59 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY PROCEDURES MARKET,
BY REGION, 2024–2031 (USD MILLION) 124
TABLE 60 LDR BRACHYTHERAPY MARKET, BY REGION, 2024–2031 (USD MILLION) 125
TABLE 61 HDR BRACHYTHERAPY MARKET, BY REGION, 2024–2031 (USD MILLION) 126
TABLE 62 PDR BRACHYTHERAPY MARKET, BY REGION, 2024–2031 (USD MILLION) 126
TABLE 63 RADIOTHERAPY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 128
TABLE 64 EXTERNAL BEAM RADIOTHERAPY TECHNOLOGIES MARKET, BY TYPE,
2024–2031 (USD MILLION) 129
TABLE 65 EXTERNAL BEAM RADIOTHERAPY TECHNOLOGIES MARKET, BY REGION,
2024–2031 (USD MILLION) 129
TABLE 66 LINACS MARKET, BY TYPE, 2024–2031 (USD MILLION) 130
TABLE 67 LINACS MARKET, BY REGION, 2024–2031 (USD MILLION) 130
TABLE 68 CONVENTIONAL LINACS MARKET, BY REGION, 2024–2031 (USD MILLION) 131
TABLE 69 STEREOTACTIC ADVANCED ELECTRON/COBALT-60 LINACS MARKET, BY TYPE, 2024–2031 (USD MILLION) 132
TABLE 70 STEREOTACTIC ADVANCED ELECTRON/COBALT-60 LINACS MARKET, BY REGION, 2024–2031 (USD MILLION) 132
TABLE 71 CYBERKNIFE MARKET, BY REGION, 2024–2031 (USD MILLION) 134
TABLE 72 GAMMA KNIFE MARKET, BY REGION, 2024–2031 (USD MILLION) 135
TABLE 73 TOMOTHERAPY MARKET, BY REGION, 2024–2031 (USD MILLION) 136
TABLE 74 MRI LINACS MARKET, BY REGION, 2024–2031 (USD MILLION) 136
TABLE 75 PARTICLE THERAPY MARKET, BY SYSTEM TYPE, 2024–2031 (USD MILLION) 137
TABLE 76 PARTICLE THERAPY MARKET, BY REGION, 2024–2031 (USD MILLION) 138
TABLE 77 CYCLOTRONS THERAPY MARKET, BY REGION, 2024–2031 (USD MILLION) 139
TABLE 78 SYNCHROTRONS THERAPY MARKET, BY REGION, 2024–2031 (USD MILLION) 140
TABLE 79 SYNCHROCYCLOTRONS THERAPY MARKET, BY REGION,
2024–2031 (USD MILLION) 141
TABLE 80 CONVENTIONAL COBALT-60 TELETHERAPY MARKET, BY REGION,
2024–2031 (USD MILLION) 142
TABLE 81 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY TECHNOLOGIES MARKET,
BY TYPE, 2024–2031 (USD MILLION) 143
TABLE 82 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY TECHNOLOGIES MARKET,
BY REGION, 2024–2031 (USD MILLION) 143
TABLE 83 SEEDS MARKET, BY REGION, 2024–2031 (USD MILLION) 144
TABLE 84 AFTERLOADERS MARKET, BY REGION, 2024–2031 (USD MILLION) 145
TABLE 85 IORT SYSTEMS MARKET, BY REGION, 2024–2031 (USD MILLION) 146
TABLE 86 APPLICATORS MARKET, BY REGION, 2024–2031 (USD MILLION) 147
TABLE 87 RADIOTHERAPY MARKET, BY END USER, 2024–2031 (USD MILLION) 149
TABLE 88 RADIOTHERAPY MARKET FOR HOSPITALS, BY REGION, 2024–2031 (USD MILLION) 150
TABLE 89 RADIOTHERAPY MARKET FOR INDEPENDENT RADIOTHERAPY CENTERS,
BY REGION, 2024–2031 (USD MILLION) 151
TABLE 90 RADIOTHERAPY MARKET, BY REGION, 2024–2031 (USD MILLION) 153
TABLE 91 NORTH AMERICA: RADIOTHERAPY MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 154
TABLE 92 NORTH AMERICA: RADIOTHERAPY MARKET, BY SYSTEM AND SOFTWARE & SERVICE, 2024–2031 (USD MILLION) 155
TABLE 93 NORTH AMERICA: RADIOTHERAPY MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 155
TABLE 94 NORTH AMERICA: EXTERNAL BEAM RADIOTHERAPY TECHNOLOGIES MARKET,
BY TYPE, 2024–2031 (USD MILLION) 155
TABLE 95 NORTH AMERICA: LINACS MARKET, BY TYPE, 2024–2031 (USD MILLION) 156
TABLE 96 NORTH AMERICA: STEREOTACTIC ADVANCED ELECTRON/COBALT-60 LINACS MARKET, BY TYPE, 2024–2031 (USD MILLION) 156
TABLE 97 NORTH AMERICA: PARTICLE THERAPY MARKET, BY SYSTEM TYPE,
2024–2031 (USD MILLION) 156
TABLE 98 NORTH AMERICA: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY TECHNOLOGIES MARKET, BY TYPE, 2024–2031 (USD MILLION) 157
TABLE 99 NORTH AMERICA: EXTERNAL BEAM RADIOTHERAPY APPLICATIONS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 157
TABLE 100 NORTH AMERICA: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY APPLICATIONS MARKET, BY TYPE, 2024–2031 (USD MILLION) 158
TABLE 101 NORTH AMERICA: EXTERNAL BEAM RADIOTHERAPY PROCEDURES MARKET,
BY TYPE, 2024–2031 (USD MILLION) 158
TABLE 102 NORTH AMERICA: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY PROCEDURES MARKET, BY TYPE, 2024–2031 (USD MILLION) 159
TABLE 103 NORTH AMERICA: RADIOTHERAPY MARKET, BY END USER,
2024–2031 (USD MILLION) 159
TABLE 104 US: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 160
TABLE 105 US: EXTERNAL BEAM RADIOTHERAPY TECHNOLOGIES MARKET, BY TYPE,
2024–2031 (USD MILLION) 160
TABLE 106 US: LINACS MARKET, BY TYPE, 2024–2031 (USD MILLION) 161
TABLE 107 US: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY TECHNOLOGIES MARKET, BY TYPE, 2024–2031 (USD MILLION) 161
TABLE 108 CANADA: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 162
TABLE 109 CANADA: EXTERNAL BEAM RADIOTHERAPY TECHNOLOGIES MARKET, BY TYPE, 2024–2031 (USD MILLION) 163
TABLE 110 CANADA: LINACS MARKET, BY TYPE, 2024–2031 (USD MILLION) 163
TABLE 111 CANADA: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY TECHNOLOGIES MARKET, BY TYPE, 2024–2031 (USD MILLION) 163
TABLE 112 EUROPE: RADIOTHERAPY MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 164
TABLE 113 EUROPE: RADIOTHERAPY MARKET, BY SYSTEM AND SOFTWARE & SERVICE, 2024–2031 (USD MILLION) 164
TABLE 114 EUROPE: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 165
TABLE 115 EUROPE: EXTERNAL BEAM RADIOTHERAPY TECHNOLOGIES MARKET, BY TYPE, 2024–2031 (USD MILLION) 165
TABLE 116 EUROPE: LINACS MARKET, BY TYPE, 2024–2031 (USD MILLION) 165
TABLE 117 EUROPE: STEREOTACTIC ADVANCED ELECTRON/COBALT-60 LINACS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 166
TABLE 118 EUROPE: PARTICLE THERAPY MARKET, BY SYSTEM TYPE,
2024–2031 (USD MILLION) 166
TABLE 119 EUROPE: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY TECHNOLOGIES MARKET, BY TYPE, 2024–2031 (USD MILLION) 166
TABLE 120 EUROPE: EXTERNAL BEAM RADIOTHERAPY APPLICATIONS MARKET, BY TYPE, 2024–2031 (USD MILLION) 167
TABLE 121 EUROPE: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY APPLICATIONS MARKET, BY TYPE, 2024–2031 (USD MILLION) 167
TABLE 122 EUROPE: EXTERNAL BEAM RADIOTHERAPY PROCEDURES MARKET, BY TYPE, 2024–2031 (USD MILLION) 168
TABLE 123 EUROPE: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY PROCEDURES MARKET, BY TYPE, 2024–2031 (USD MILLION) 168
TABLE 124 EUROPE: RADIOTHERAPY MARKET, BY END USER, 2024–2031 (USD MILLION) 169
TABLE 125 GERMANY: RADIOTHERAPY MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 170
TABLE 126 GERMANY: EXTERNAL BEAM RADIOTHERAPY TECHNOLOGIES MARKET, BY TYPE, 2024–2031 (USD MILLION) 170
TABLE 127 GERMANY: LINACS MARKET, BY TYPE, 2024–2031 (USD MILLION) 170
TABLE 128 GERMANY: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY TECHNOLOGIES MARKET, BY TYPE, 2024–2031 (USD MILLION) 171
TABLE 129 FRANCE: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 172
TABLE 130 FRANCE: EXTERNAL BEAM RADIOTHERAPY TECHNOLOGIES MARKET, BY TYPE, 2024–2031 (USD MILLION) 172
TABLE 131 FRANCE: LINACS MARKET, BY TYPE, 2024–2031 (USD MILLION) 173
TABLE 132 FRANCE: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY TECHNOLOGIES MARKET, BY TYPE, 2024–2031 (USD MILLION) 173
TABLE 133 UK: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 174
TABLE 134 UK: EXTERNAL BEAM RADIOTHERAPY TECHNOLOGIES MARKET, BY TYPE,
2024–2031 (USD MILLION) 175
TABLE 135 UK: LINACS MARKET, BY TYPE, 2024–2031 (USD MILLION) 175
TABLE 136 UK: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY TECHNOLOGIES MARKET, BY TYPE, 2024–2031 (USD MILLION) 175
TABLE 137 SPAIN: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 176
TABLE 138 SPAIN: EXTERNAL BEAM RADIOTHERAPY TECHNOLOGIES MARKET, BY TYPE, 2024–2031 (USD MILLION) 177
TABLE 139 SPAIN: LINACS MARKET, BY TYPE, 2024–2031 (USD MILLION) 177
TABLE 140 SPAIN: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY TECHNOLOGIES MARKET, BY TYPE, 2024–2031 (USD MILLION) 177
TABLE 141 ITALY: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 178
TABLE 142 ITALY: EXTERNAL BEAM RADIOTHERAPY TECHNOLOGIES MARKET, BY TYPE,
2024–2031 (USD MILLION) 179
TABLE 143 ITALY: LINACS MARKET, BY TYPE, 2024–2031 (USD MILLION) 179
TABLE 144 ITALY: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY TECHNOLOGIES MARKET, BY TYPE, 2024–2031 (USD MILLION) 179
TABLE 145 REST OF EUROPE: RADIOTHERAPY MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 180
TABLE 146 REST OF EUROPE: EXTERNAL BEAM RADIOTHERAPY TECHNOLOGIES MARKET,
BY TYPE, 2024–2031 (USD MILLION) 180
TABLE 147 REST OF EUROPE: LINACS MARKET, BY TYPE, 2024–2031 (USD MILLION) 181
TABLE 148 REST OF EUROPE: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY TECHNOLOGIES MARKET, BY TYPE, 2024–2031 (USD MILLION) 181
TABLE 149 ASIA PACIFIC: RADIOTHERAPY MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 182
TABLE 150 ASIA PACIFIC: RADIOTHERAPY MARKET, BY SYSTEM AND SOFTWARE & SERVICE, 2024–2031 (USD MILLION) 183
TABLE 151 ASIA PACIFIC: RADIOTHERAPY MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 183
TABLE 152 ASIA PACIFIC: EXTERNAL BEAM RADIOTHERAPY TECHNOLOGIES MARKET,
BY TYPE, 2024–2031 (USD MILLION) 183
TABLE 153 ASIA PACIFIC: LINACS MARKET, BY TYPE, 2024–2031 (USD MILLION) 184
TABLE 154 ASIA PACIFIC: STEREOTACTIC ADVANCED ELECTRON/COBALT-60 LINACS MARKET, BY TYPE, 2024–2031 (USD MILLION) 184
TABLE 155 ASIA PACIFIC: PARTICLE THERAPY MARKET, BY SYSTEM TYPE,
2024–2031 (USD MILLION) 184
TABLE 156 ASIA PACIFIC: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY TECHNOLOGIES MARKET, BY TYPE, 2024–2031 (USD MILLION) 185
TABLE 157 ASIA PACIFIC: EXTERNAL BEAM RADIOTHERAPY APPLICATIONS MARKET, BY TYPE, 2024–2031 (USD MILLION) 185
TABLE 158 ASIA PACIFIC: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY APPLICATIONS MARKET, BY TYPE, 2024–2031 (USD MILLION) 186
TABLE 159 ASIA PACIFIC: EXTERNAL BEAM RADIOTHERAPY PROCEDURES MARKET, BY TYPE, 2024–2031 (USD MILLION) 186
TABLE 160 ASIA PACIFIC: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY PROCEDURES MARKET, BY TYPE, 2024–2031 (USD MILLION) 187
TABLE 161 ASIA PACIFIC: RADIOTHERAPY MARKET, BY END USER, 2024–2031 (USD MILLION) 187
TABLE 162 JAPAN: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 188
TABLE 163 JAPAN: EXTERNAL BEAM RADIOTHERAPY TECHNOLOGIES MARKET, BY TYPE, 2024–2031 (USD MILLION) 188
TABLE 164 JAPAN: LINACS MARKET, BY TYPE, 2024–2031 (USD MILLION) 189
TABLE 165 JAPAN: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY TECHNOLOGIES MARKET, BY TYPE, 2024–2031 (USD MILLION) 189
TABLE 166 CHINA: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 190
TABLE 167 CHINA: EXTERNAL BEAM RADIOTHERAPY TECHNOLOGIES MARKET, BY TYPE, 2024–2031 (USD MILLION) 191
TABLE 168 CHINA: LINACS MARKET, BY TYPE, 2024–2031 (USD MILLION) 191
TABLE 169 CHINA: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY TECHNOLOGIES MARKET, BY TYPE, 2024–2031 (USD MILLION) 191
TABLE 170 INDIA: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 192
TABLE 171 INDIA: EXTERNAL BEAM RADIOTHERAPY TECHNOLOGIES MARKET, BY TYPE,
2024–2031 (USD MILLION) 193
TABLE 172 INDIA: LINACS MARKET, BY TYPE, 2024–2031 (USD MILLION) 193
TABLE 173 INDIA: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY TECHNOLOGIES MARKET, BY TYPE, 2024–2031 (USD MILLION) 193
TABLE 174 SOUTH KOREA: RADIOTHERAPY MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 194
TABLE 175 SOUTH KOREA: EXTERNAL BEAM RADIOTHERAPY TECHNOLOGIES MARKET,
BY TYPE, 2024–2031 (USD MILLION) 195
TABLE 176 SOUTH KOREA: LINACS MARKET, BY TYPE, 2024–2031 (USD MILLION) 195
TABLE 177 SOUTH KOREA: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY TECHNOLOGIES MARKET, BY TYPE, 2024–2031 (USD MILLION) 195
TABLE 178 AUSTRALIA: RADIOTHERAPY MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 196
TABLE 179 AUSTRALIA: EXTERNAL BEAM RADIOTHERAPY TECHNOLOGIES MARKET,
BY TYPE, 2024–2031 (USD MILLION) 197
TABLE 180 AUSTRALIA: LINACS MARKET, BY TYPE, 2024–2031 (USD MILLION) 197
TABLE 181 AUSTRALIA: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY TECHNOLOGIES MARKET, BY TYPE, 2024–2031 (USD MILLION) 197
TABLE 182 REST OF ASIA PACIFIC: RADIOTHERAPY MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 198
TABLE 183 REST OF ASIA PACIFIC: EXTERNAL BEAM RADIOTHERAPY TECHNOLOGIES MARKET, BY TYPE, 2024–2031 (USD MILLION) 198
TABLE 184 REST OF ASIA PACIFIC: LINACS MARKET, BY TYPE, 2024–2031 (USD MILLION) 199
TABLE 185 REST OF ASIA PACIFIC: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY TECHNOLOGIES MARKET, BY TYPE, 2024–2031 (USD MILLION) 199
TABLE 186 LATIN AMERICA: RADIOTHERAPY MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 200
TABLE 187 LATIN AMERICA: RADIOTHERAPY MARKET, BY SYSTEM AND SOFTWARE & SERVICE, 2024–2031 (USD MILLION) 200
TABLE 188 LATIN AMERICA: RADIOTHERAPY MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 200
TABLE 189 LATIN AMERICA: EXTERNAL BEAM RADIOTHERAPY TECHNOLOGIES MARKET,
BY TYPE, 2024–2031 (USD MILLION) 200
TABLE 190 LATIN AMERICA: LINACS MARKET, BY TYPE, 2024–2031 (USD MILLION) 201
TABLE 191 LATIN AMERICA: STEREOTACTIC ADVANCED ELECTRON/COBALT-60 LINACS MARKET, BY TYPE, 2024–2031 (USD MILLION) 201
TABLE 192 LATIN AMERICA: PARTICLE THERAPY MARKET, BY SYSTEM TYPE,
2024–2031 (USD MILLION) 201
TABLE 193 LATIN AMERICA: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY TECHNOLOGIES MARKET, BY TYPE, 2024–2031 (USD MILLION) 202
TABLE 194 LATIN AMERICA: EXTERNAL BEAM RADIOTHERAPY APPLICATIONS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 203
TABLE 195 LATIN AMERICA: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY APPLICATIONS MARKET, BY TYPE, 2024–2031 (USD MILLION) 203
TABLE 196 LATIN AMERICA: EXTERNAL BEAM RADIOTHERAPY PROCEDURES MARKET,
BY TYPE, 2024–2031 (USD MILLION) 204
TABLE 197 LATIN AMERICA: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY PROCEDURES MARKET, BY TYPE, 2024–2031 (USD MILLION) 204
TABLE 198 LATIN AMERICA: RADIOTHERAPY MARKET, BY END USER,
2024–2031 (USD MILLION) 205
TABLE 199 BRAZIL: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 206
TABLE 200 BRAZIL: EXTERNAL BEAM RADIOTHERAPY TECHNOLOGIES MARKET,
BY TYPE, 2024–2031 (USD MILLION) 206
TABLE 201 BRAZIL: LINACS MARKET, BY TYPE, 2024–2031 (USD MILLION) 206
TABLE 202 BRAZIL: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY TECHNOLOGIES MARKET, BY TYPE, 2024–2031 (USD MILLION) 207
TABLE 203 MEXICO: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 208
TABLE 204 MEXICO: EXTERNAL BEAM RADIOTHERAPY TECHNOLOGIES MARKET, BY TYPE, 2024–2031 (USD MILLION) 208
TABLE 205 MEXICO: LINACS MARKET, BY TYPE, 2024–2031 (USD MILLION) 208
TABLE 206 MEXICO: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY TECHNOLOGIES MARKET, BY TYPE, 2024–2031 (USD MILLION) 209
TABLE 207 REST OF LATIN AMERICA: RADIOTHERAPY MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 209
TABLE 208 REST OF LATIN AMERICA: EXTERNAL BEAM RADIOTHERAPY TECHNOLOGIES MARKET, BY TYPE, 2024–2031 (USD MILLION) 210
TABLE 209 REST OF LATIN AMERICA: LINACS MARKET, BY TYPE, 2024–2031 (USD MILLION) 210
TABLE 210 REST OF LATIN AMERICA: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY TECHNOLOGIES MARKET, BY TYPE, 2024–2031 (USD MILLION) 210
TABLE 211 MIDDLE EAST & AFRICA: RADIOTHERAPY MARKET, BY REGION,
2024–2031 (USD MILLION) 211
TABLE 212 MIDDLE EAST & AFRICA: RADIOTHERAPY MARKET, BY SYSTEM AND SOFTWARE & SERVICE, 2024–2031 (USD MILLION) 211
TABLE 213 MIDDLE EAST & AFRICA: RADIOTHERAPY MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 212
TABLE 214 MIDDLE EAST & AFRICA: EXTERNAL BEAM RADIOTHERAPY TECHNOLOGIES MARKET, BY TYPE, 2024–2031 (USD MILLION) 212
TABLE 215 MIDDLE EAST & AFRICA: LINACS MARKET, BY TYPE, 2024–2031 (USD MILLION) 212
TABLE 216 MIDDLE EAST & AFRICA: STEREOTACTIC ADVANCED ELECTRON/COBALT-60 LINACS MARKET, BY TYPE, 2024–2031 (USD MILLION) 213
TABLE 217 MIDDLE EAST & AFRICA: PARTICLE THERAPY MARKET, BY SYSTEM TYPE,
2024–2031 (USD MILLION) 213
TABLE 218 MIDDLE EAST & AFRICA: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY TECHNOLOGIES MARKET, BY TYPE, 2024–2031 (USD MILLION) 213
TABLE 219 MIDDLE EAST & AFRICA: EXTERNAL BEAM RADIOTHERAPY APPLICATIONS MARKET, BY TYPE, 2024–2031 (USD MILLION) 214
TABLE 220 MIDDLE EAST & AFRICA: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY APPLICATIONS MARKET, BY TYPE, 2024–2031 (USD MILLION) 214
TABLE 221 MIDDLE EAST & AFRICA: EXTERNAL BEAM RADIOTHERAPY PROCEDURES MARKET, BY TYPE, 2024–2031 (USD MILLION) 215
TABLE 222 MIDDLE EAST & AFRICA: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY PROCEDURES MARKET, BY TYPE, 2024–2031 (USD MILLION) 215
TABLE 223 MIDDLE EAST & AFRICA: RADIOTHERAPY MARKET, BY END USER,
2024–2031 (USD MILLION) 216
TABLE 224 GCC COUNTRIES: RADIOTHERAPY MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 217
TABLE 225 GCC COUNTRIES: EXTERNAL BEAM RADIOTHERAPY TECHNOLOGIES MARKET,
BY TYPE, 2024–2031 (USD MILLION) 217
TABLE 226 GCC COUNTRIES: LINACS MARKET, BY TYPE, 2024–2031 (USD MILLION) 217
TABLE 227 GCC COUNTRIES: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY TECHNOLOGIES MARKET, BY TYPE, 2024–2031 (USD MILLION) 218
TABLE 228 REST OF MIDDLE EAST & AFRICA: RADIOTHERAPY MARKET,
BY TECHNOLOGY, 2024–2031 (USD MILLION) 218
TABLE 229 REST OF MIDDLE EAST & AFRICA: EXTERNAL BEAM RADIOTHERAPY TECHNOLOGIES MARKET, BY TYPE, 2024–2031 (USD MILLION) 219
TABLE 230 REST OF MIDDLE EAST & AFRICA: LINACS MARKET, BY TYPE,
2024–2031 (USD MILLION) 219
TABLE 231 REST OF MIDDLE EAST & AFRICA: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY TECHNOLOGIES MARKET, BY TYPE,
2024–2031 (USD MILLION) 219
TABLE 232 OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS IN RADIOTHERAPY MARKET, JANUARY 2022–MAY 2026 220
TABLE 233 RADIOTHERAPY MARKET: DEGREE OF COMPETITION 226
TABLE 234 RADIOTHERAPY MARKET: REGION FOOTPRINT 230
TABLE 235 RADIOTHERAPY MARKET: TECHNOLOGY FOOTPRINT 230
TABLE 236 RADIOTHERAPY MARKET: APPLICATION FOOTPRINT 231
TABLE 237 RADIOTHERAPY MARKET: END-USER FOOTPRINT 232
TABLE 238 RADIOTHERAPY MARKET: DETAILED LIST OF KEY STARTUP/SME PLAYERS 234
TABLE 239 RADIOTHERAPY MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES 235
TABLE 240 RADIOTHERAPY MARKET: PRODUCT LAUNCHES & APPROVALS,
JANUARY 2022–MAY 2026 238
TABLE 241 RADIOTHERAPY MARKET: DEALS, JANUARY 2022–MAY 2026 240
TABLE 242 RADIOTHERAPY MARKET: EXPANSIONS, JANUARY 2022–MAY 2026 241
TABLE 243 SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW 242
TABLE 244 SIEMENS HEALTHINEERS AG: PRODUCTS/SOLUTIONS/SERVICES OFFERED 244
TABLE 245 SIEMENS HEALTHINEERS AG: PRODUCT APPROVALS, JANUARY 2022–MAY 2026 245
TABLE 246 SIEMENS HEALTHINEERS AG: DEALS, JANUARY 2022−MAY 2026 246
TABLE 247 ELEKTA: COMPANY OVERVIEW 249
TABLE 248 ELEKTA: PRODUCTS/SOLUTIONS/SERVICES OFFERED 250
TABLE 249 ELEKTA: PRODUCTS LAUNCHES & APPROVALS, JANUARY 2022−MAY 2026 251
TABLE 250 ELEKTA: DEALS, JANUARY 2022−MAY 2026 252
TABLE 251 ELEKTA: EXPANSIONS, JANUARY 2022−MAY 2026 254
TABLE 252 ACCURAY INCORPORATED: COMPANY OVERVIEW 255
TABLE 253 ACCURAY INCORPORATED: PRODUCTS/SOLUTIONS/SERVICES OFFERED 256
TABLE 254 ACCURAY INCORPORATED: PRODUCT LAUNCHES & APPROVALS,
JANUARY 2022−MAY 2026 257
TABLE 255 ACCURAY INCORPORATED: DEALS, JANUARY 2022−MAY 2026 258
TABLE 256 ACCURAY INCORPORATED: EXPANSIONS, JANUARY 2022−MAY 2026 259
TABLE 257 IBA WORLDWIDE: COMPANY OVERVIEW 260
TABLE 258 IBA WORLDWIDE: PRODUCTS/SOLUTIONS/SERVICES OFFERED 261
TABLE 259 IBA WORLDWIDE: PRODUCT LAUNCHES, JANUARY 2022−MAY 2026 262
TABLE 260 IBA WORLDWIDE: DEALS, JANUARY 2022−MAY 2026 263
TABLE 261 VIEWRAY SYSTEMS, INC.: COMPANY OVERVIEW 266
TABLE 262 VIEWRAY SYSTEMS, INC.: PRODUCTS/SOLUTIONS/SERVICES OFFERED 266
TABLE 263 VIEWRAY SYSTEMS, INC.: PRODUCT APPROVALS, JANUARY 2022−MAY 2026 267
TABLE 264 VIEWRAY SYSTEMS, INC.: DEALS, JANUARY 2022−MAY 2026 267
TABLE 265 GT MEDICAL TECHNOLOGIES, INC.: COMPANY OVERVIEW 269
TABLE 266 GT MEDICAL TECHNOLOGIES, INC.: PRODUCTS/SOLUTIONS/SERVICES OFFERED 269
TABLE 267 HITACHI HIGH-TECH CORPORATION: COMPANY OVERVIEW 270
TABLE 268 HITACHI HIGH-TECH CORPORATION: PRODUCTS/SOLUTIONS/SERVICES OFFERED 272
TABLE 269 HITACHI HIGH-TECH CORPORATION: DEALS, JANUARY 2022−MAY 2026 272
TABLE 270 SUMITOMO HEAVY INDUSTRIES, LTD.: COMPANY OVERVIEW 273
TABLE 271 SUMITOMO HEAVY INDUSTRIES, LTD.: PRODUCTS/SOLUTIONS/
SERVICES OFFERED 274
TABLE 272 ZEISS GROUP : COMPANY OVERVIEW 275
TABLE 273 ZEISS GROUP: PRODUCTS/SOLUTIONS/SERVICES OFFERED 277
TABLE 274 ZEISS GROUP: PRODUCT LAUNCHES, JANUARY 2022−MAY 2026 277
TABLE 275 MIM SOFTWARE INC.: COMPANY OVERVIEW 278
TABLE 276 MIM SOFTWARE INC.: PRODUCTS/SOLUTIONS/SERVICES OFFERED 278
TABLE 277 MIM SOFTWARE INC.: PRODUCT LAUNCHES & APPROVALS,
JANUARY 2022−MAY 2026 279
TABLE 278 MIM SOFTWARE INC.: DEALS, JANUARY 2022−MAY 2026 279
TABLE 279 PANACEA MEDICAL TECHNOLOGIES PVT. LTD.: COMPANY OVERVIEW 280
TABLE 280 PANACEA MEDICAL TECHNOLOGIES PVT. LTD.: PRODUCTS/SOLUTIONS/
SERVICES OFFERED 280
TABLE 281 PANACEA MEDICAL TECHNOLOGIES PVT. LTD.: PRODUCT LAUNCHES ,
JANUARY 2022−MAY 2026 281
TABLE 282 PANACEA MEDICAL TECHNOLOGIES PVT. LTD.: DEALS, JANUARY 2022−MAY 2026 281
TABLE 283 PROVISION HEALTHCARE: COMPANY OVERVIEW 282
TABLE 284 PROVISION HEALTHCARE: PRODUCTS/SOLUTIONS/SERVICES OFFERED 282
TABLE 285 MEVION MEDICAL SYSTEMS: COMPANY OVERVIEW 283
TABLE 286 MEVION MEDICAL SYSTEMS: PRODUCTS/SOLUTIONS/SERVICES OFFERED 283
TABLE 287 MEVION MEDICAL SYSTEMS: PRODUCT LAUNCHES & APPROVALS,
JANUARY 2022−MAY 2026 284
TABLE 288 MEVION MEDICAL SYSTEMS: DEALS, JANUARY 2022−MAY 2026 284
TABLE 289 KONINKLIJKE PHILIPS N.V.: COMPANY OVERVIEW 286
TABLE 290 KONINKLIJKE PHILIPS N.V.: PRODUCTS/SOLUTIONS/SERVICES OFFERED 287
TABLE 291 KONINKLIJKE PHILIPS N.V.: PRODUCT LAUNCHES, JANUARY 2022−MAY 2026 288
TABLE 292 SHINVA MEDICAL INSTRUMENT CO., LTD.: COMPANY OVERVIEW 289
TABLE 293 BRAINLAB AG: COMPANY OVERVIEW 290
TABLE 294 RAYSEARCH LABORATORIES: COMPANY OVERVIEW 291
TABLE 295 INTRAOP MEDICAL, INC.: COMPANY OVERVIEW 292
TABLE 296 OPTIVUS PROTON THERAPY, INC.: COMPANY OVERVIEW 293
TABLE 297 BEBIG MEDICAL: COMPANY OVERVIEW 294
TABLE 298 P-CURE: COMPANY OVERVIEW 295
TABLE 299 THERAGENICS CORPORATION: COMPANY OVERVIEW 296
TABLE 300 PROTOM INTERNATIONAL: COMPANY OVERVIEW 297
TABLE 301 DOSISOFT SA: COMPANY OVERVIEW 298
TABLE 302 ISOAID, LLC: COMPANY OVERVIEW 299
TABLE 303 MAGNETTX ONCOLOGY SOLUTIONS LTD.: COMPANY OVERVIEW 300
TABLE 304 RADIOTHERAPY MARKET: RESEARCH ASSUMPTIONS 314
FIGURE 1 RADIOTHERAPY MARKET SEGMENTATION AND REGIONAL SCOPE 30
FIGURE 2 DURATION COVERED 32
FIGURE 3 MARKET SCENARIO 34
FIGURE 4 GLOBAL RADIOTHERAPY MARKET, 2024–2031 34
FIGURE 5 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN
RADIOTHERAPY MARKET, 2022–2026 35
FIGURE 6 DISRUPTIONS INFLUENCING GROWTH OF RADIOTHERAPY MARKET 36
FIGURE 7 HIGH-GROWTH SEGMENTS IN RADIOTHERAPY MARKET, 2026–2031 37
FIGURE 8 ASIA PACIFIC TO REGISTER HIGHEST CAGR IN RADIOTHERAPY
MARKET DURING FORECAST PERIOD 38
FIGURE 9 ADVANCEMENTS IN AI AND ADAPTIVE RADIOTHERAPY ENHANCE
TREATMENT PRECISION 39
FIGURE 10 NORTH AMERICA TO ACCOUNT FOR LARGEST MARKET SHARE
DURING STUDY PERIOD 40
FIGURE 11 EXTERNAL BEAM RADIATION THERAPY SEGMENT ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN MARKET IN 2025 40
FIGURE 12 CHINA TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD 41
FIGURE 13 RADIOTHERAPY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 42
FIGURE 14 RADIOTHERAPY MARKET: PORTER’S FIVE FORCES ANALYSIS 55
FIGURE 15 RADIOTHERAPY MARKET: VALUE CHAIN ANALYSIS 58
FIGURE 16 RADIOTHERAPY MARKET: ECOSYSTEM ANALYSIS 59
FIGURE 17 AVERAGE SELLING PRICE TREND OF RADIOTHERAPY SYSTEMS,
BY REGION, 2023–2025 (USD) 61
FIGURE 18 IMPORT DATA FOR HS CODE 902214-COMPLIANT PRODUCTS,
BY COUNTRY, 2021–2025 62
FIGURE 19 EXPORT DATA FOR HS CODE 902214-COMPLIANT PRODUCTS,
BY COUNTRY, 2021–2025 63
FIGURE 20 RADIOTHERAPY MARKET: TRENDS/DISRUPTIONS IMPACTING
CUSTOMER BUSINESS 65
FIGURE 21 RADIOTHERAPY MARKET: INVESTMENT & FUNDING SCENARIO, 2019–2023 65
FIGURE 22 RADIOTHERAPY MARKET: NUMBER OF INVESTOR DEALS, BY KEY PLAYER,
2019–2023 66
FIGURE 23 VALUE OF INVESTOR DEALS IN RADIOTHERAPY MARKET, BY KEY PLAYER,
2019–2023 66
FIGURE 24 PATENT ANALYSIS FOR RADIOTHERAPY MARKET,
JANUARY 2016–DECEMBER 2025 75
FIGURE 25 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS
OF RADIOTHERAPY SYSTEMS 92
FIGURE 26 KEY BUYING CRITERIA FOR RADIOTHERAPY SYSTEMS 93
FIGURE 27 NORTH AMERICA: RADIOTHERAPY MARKET SNAPSHOT 154
FIGURE 28 ASIA PACIFIC: RADIOTHERAPY MARKET SNAPSHOT 182
FIGURE 29 REVENUE ANALYSIS OF KEY PLAYERS IN RADIOTHERAPY MARKET, 2021−2025 225
FIGURE 30 MARKET SHARE ANALYSIS OF KEY PLAYERS IN RADIOTHERAPY MARKET, 2025 226
FIGURE 31 RADIOTHERAPY MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025 228
FIGURE 32 RADIOTHERAPY MARKET: COMPANY FOOTPRINT 229
FIGURE 33 RADIOTHERAPY MARKET: COMPANY EVALUATION MATRIX
(STARTUPS/SMES), 2025 233
FIGURE 34 EV/EBITDA OF KEY VENDORS 236
FIGURE 35 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK
BETA OF KEY VENDORS 236
FIGURE 36 RADIOTHERAPY MARKET: BRAND COMPARATIVE ANALYSIS 237
FIGURE 37 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT 243
FIGURE 38 ELEKTA: COMPANY SNAPSHOT 250
FIGURE 39 ACCURAY INCORPORATED: COMPANY SNAPSHOT 256
FIGURE 40 IBA WORLDWIDE: COMPANY SNAPSHOT 261
FIGURE 41 HITACHI HIGH-TECH CORPORATION: COMPANY SNAPSHOT 271
FIGURE 42 SUMITOMO HEAVY INDUSTRIES, LTD.: COMPANY SNAPSHOT 274
FIGURE 43 ZEISS GROUP: COMPANY SNAPSHOT 276
FIGURE 44 KONINKLIJKE PHILIPS N.V.: COMPANY SNAPSHOT 287
FIGURE 45 RESEARCH DESIGN 301
FIGURE 46 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE,
DESIGNATION, AND REGION 304
FIGURE 47 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND
DEMAND-SIDE PARTICIPANTS 306
FIGURE 48 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING 307
FIGURE 49 RADIOTHERAPY MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE ESTIMATION) 308
FIGURE 50 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS (2025) 309
FIGURE 51 RADIOTHERAPY MARKET: MARKET SIZE ESTIMATION METHODOLOGY 310
FIGURE 52 MARKET SIZE ESTIMATION: TOP-DOWN APPROACH 311
FIGURE 53 DATA TRIANGULATION METHODOLOGY 313